Neuroscience startup BrainSight AI raises $5 Mn

Deep-tech neuroscience startup BrainSight AI has raised $5 million in a pre-Series A funding round led by IAN Alpha Fund, along with participation from IvyCap Ventures, Silver Needle, and its existing investors.

The Bengaluru-based company had previously raised $925K from Pfizer and others.

The fresh funds will be utilized to expand its presence in India, increasing reach in Tier I and Tier II cities, making a foray into Africa, Southeast Asia, the US, and allied markets, and enhancing R&D capabilities, BrainSight said in a press release.

Co-founded in 2019 by Laina Emmanuel and Rimjhim Agrawal, BrainSight AI aims to enable greater precision in the diagnosis and treatment planning of neuro-oncological and neuropsychiatric disorders. The platform combines artificial intelligence and neuroscience to enable precision in neurological and psychiatric investigations for accelerated patient outcomes.

According to BrainSight, its platform products include Voxelbox, which provides clinicians with access to an fMRI processing engine and machine-learning models; and Snowdrop, a patient care app that enables compliance with treatment schedules and builds patient profiles.

Currently, BrainSight AI asserts that it collaborates with over 40 leading hospitals across India, particularly in neurosurgery and radiology departments, focusing on brain tumor cases. The company is now expanding its solutions to neurological and psychiatric disorders, paving the way for a more holistic approach to brain care.

BrainSight AI helps to understand how the physiology of the brain correlates to its functions by mapping macro-scale neural connections in the brain to enable precise diagnosis and prognosis of neuro-oncological and neuropsychiatric disorders.